90 related articles for article (PubMed ID: 30638756)
21. Histopathological findings in extended prostate biopsy with PSA < or = 4 ng/mL.
Leite KR; Srougi M; Dall'Oglio MF; Sanudo A; Camara-Lopes LH
Int Braz J Urol; 2008; 34(3):283-90; discussion 290-2. PubMed ID: 18601758
[TBL] [Abstract][Full Text] [Related]
22. Early diagnosis of prostate cancer in the Western Cape.
Heyns CF; Naudé AM; Visser AJ; Marais DC; Stopforth HB; Nyarko JK; Stellmacher GA
S Afr Med J; 2001 Aug; 91(8):679-84. PubMed ID: 11584784
[TBL] [Abstract][Full Text] [Related]
23. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.
Stattin P; Johansson R; Damber JE; Hellström M; Hugosson J; Lundgren R; Varenhorst E; Johansson JE
Scand J Urol Nephrol; 2003; 37(6):461-5. PubMed ID: 14675917
[TBL] [Abstract][Full Text] [Related]
24. Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.
Ranasinghe WK; Kim SP; Lawrentschuk N; Sengupta S; Hounsome L; Barber J; Jones R; Davis P; Bolton D; Persad R
BJU Int; 2014 Jan; 113(1):77-83. PubMed ID: 24053128
[TBL] [Abstract][Full Text] [Related]
25. Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Luján M; Páez A; Pascual C; Angulo J; Miravalles E; Berenguer A
Eur Urol; 2006 Dec; 50(6):1234-40; discussion 1239-40. PubMed ID: 16704893
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen velocity in untreated, localized prostate cancer.
Venkitaraman R; Norman A; Woode-Amissah R; Dearnaley D; Horwich A; Huddart R; Parker C
BJU Int; 2008 Jan; 101(2):161-4. PubMed ID: 17850368
[TBL] [Abstract][Full Text] [Related]
27. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal screening for prostate cancer with prostate-specific antigen.
Smith DS; Catalona WJ; Herschman JD
JAMA; 1996 Oct 23-30; 276(16):1309-15. PubMed ID: 8861989
[TBL] [Abstract][Full Text] [Related]
29. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
[TBL] [Abstract][Full Text] [Related]
31. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
32. Should men with serum prostate-specific antigen < or =4 ng/ml and normal digital rectal examination undergo a prostate biopsy? A literature review.
Pepe P; Panella P; D'Arrigo L; Savoca F; Pennisi M; Aragona F
Oncology; 2006; 70(2):81-9. PubMed ID: 16601365
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.
Lodding P; Aus G; Bergdahl S; Frösing R; Lilja H; Pihl CG; Hugosson J
J Urol; 1998 Mar; 159(3):899-903. PubMed ID: 9474178
[TBL] [Abstract][Full Text] [Related]
35. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
Mettlin C; Murphy GP; Lee F; Littrup PJ; Chesley A; Babaian R; Badalament R; Kane RA; Mostofi FK
Cancer; 1993 Sep; 72(5):1701-8. PubMed ID: 7688658
[TBL] [Abstract][Full Text] [Related]
37. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
[TBL] [Abstract][Full Text] [Related]
38. [Repeat prostate biopsies following a first negative biopsy in a context of an elevated prostate specific antigen].
Floc'h AP; Benmeziani R; Delpech PO; Doré B; Fromont G; Irani J
Prog Urol; 2012 Oct; 22(12):718-24. PubMed ID: 22999119
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
40. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.
Jacobsen SJ; Katusic SK; Bergstralh EJ; Oesterling JE; Ohrt D; Klee GG; Chute CG; Lieber MM
JAMA; 1995 Nov; 274(18):1445-9. PubMed ID: 7474190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]